Origin and diversification of the clonogenic cell in multiple myeloma: Lessons from the immunoglobulin repertoire

Leukemia

Volumn 14, Issue 10, 2000, Pages 1718-1726

  Kosmas, C ^a   Stamatopoulos, K ^a   Stavroyianni, N ^a   Zoi, K ^a   Belessi, C ^a   Viniou, N ^a   Kollia, P ^a   Yataganas, X ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Immunoglobulin genes; Multiple myeloma; Somatic hypermutation

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIBODY; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; COLD AGGLUTININ; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MESSENGER RNA; NUCLEOTIDE; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIBODY SPECIFICITY; AUTOIMMUNITY; B LYMPHOCYTE; BINDING AFFINITY; BONE MARROW CELL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; CYTOLOGY; GENE INSERTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC HETEROGENEITY; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LYMPHOPROLIFERATIVE DISEASE; MEMORY CELL; MOLECULAR CLONING; MULTIPLE MYELOMA; MYELOMA CELL; ONTOGENY; PATHOGENICITY; PLASMA CELL; PRIORITY JOURNAL; PROTEIN VARIANT; REVIEW; SOMATIC MUTATION; STEM CELL;

EID: 0033815486     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401908     Document Type: Review

References (93)

1. Markers of multiple hematopoietic stem cell lineages in multiple myeloma
2. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma
3. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human myeloma tumor cells
4. Mutations in the Fas antigen in patients with multiple myeloma
5. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
6. Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8
7. Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
8. Architecture of the human B-cell antigen receptors
9. Definition of the human immunoglobulin variable lambda gene subgroups
10. The physical organization of the human immunoglobulin heavy chain gene
11. Expressed human immunoglobulin κ genes and their hypermutation
12. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells
13. Activation of Vκ gene rearrangement in pre-B cells follows the expression of membrane-bound immunoglobulin heavy chains
14. Lambda chain expression at different stages of ontogeny in C57BL/6, BALB/c and SJL mice
15. Immunoglobulin heavy and light chain genes rearrange independently at early stages of B-cell development
16. Unusual patterns of immunoglobulin gene rearrangement and expression during human B-cell ontogeny: Human B-cells can simultaneously express cell surface κ and λ light chains
17. Passenger transgenes reveal intrinsic specificity of the antibody hypermutation mechanism: Clustering, polarity, and specific hot spots
18. Negative selection of lymphocytes
19. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma
20. Purified CD34 'Lin Thy' stem cells do not contain clonal myeloma cells
21. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma
22. 1 cells in the blood of patients with multiple myeloma express CD19 and Ig mRNA and have patient-specific IgH VDJ gene rearrangements
23. Quantification of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma
24. The bone marrow of multiple myeloma patients contains B-cell populations at different stages of differentiation that are clonally related to the malignant plasma cell
25. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cu sequence in immunoglobulin (IgG)-and IgA-secreting multiple myelomas
26. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell
27. Immunological memory
28. Promiscuous translocations into immunoglobulin heavy chain switc regions in multiple myeloma
29. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
30. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
31. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma
32. Expression of novel genes in human chromosomal locus 11q13
33. Plasmacytomagenesis in mice: Model of neoplastic development dependent upon chromosomal translocations
34. Dysregulation of c-myc in multiple myeloma
35. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
36. Myeloma lg heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity
37. The role of clonal selection and somatic mutation in autoimmunity
38. The CDR1 sequences of a major proportion of human germline Ig V(H) genes are inherently susceptible to amino acid replacement
39. Antigen selection of multiple myeloma clonogenic B cells as evidenced by V(H) and V(L) gene mutations
40. Antibody engineering for the analysis of affinity maturation of an anti-hapten response
41. Ig V(H) gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance
42. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
43. Hodgkin's and Reed-Sternberg cells in Hodgkin's disease represent the out-growth of a dominant tumor clone derived from (crippled) germinal center B cells
44. V(H) gene usage in multiple myeloma: Complete abscence of the V(H)4.21 (V(H)4-34) gene
45. Immunoglobulin V(H)4 gene usage in B lymphoid leukaemias
46. 1 B-cell chronic lymphocytic leukemia and displaying autoantibody activity
47. Skewed rearrangement of the V(H) 4-21 gene during pre-B acute lymphoblastic leukemia
48. Preferential use of the V(H)4 lg gene family by diffuse large-cell lymphoma
49. V(H) restriction among human cold agglutinins. The V(H) 4-21 gene segment is required to encode anti-1 and anti-i specificities
50. Analysis of κ light chain variable region in multiple myeloma
51. Similar patterns of Vκ gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma
52. Variable κ gene rearrangement in lymphoproliferative disorders and analysis of Vκ gene usage, VJ joining and somatic mutation
53. Myeloma V(L) and V(H) sequences reveal a complementary imprint of antigen selection in tumor cells
54. Characterization of the immunoglobulin light chain variable region gene expressed in multiple myeloma
55. Rapid expansion of human immunoglobulin repertoire (V(H), V(κ), V(λ)) expressed in early fetal bone marrow
56. Autoantibody-encoding κ L chain genes frequently rearranged in λ L chain-expressing chronic lymphocytic leukemia
57. Somatic hypermutation of immunoglobulin genes: Focus on follicular lymphoma and multiple myeloma
58. Identification of a new human Vλ gene family-VλX
59. Mechanistic and selective constraints act on the establishment of VλJλ junctions in the B cell repertoire
60. Molecular mechanisms and selection influence the generation of the human Vλ-Jλ gene repertoire
61. Immunoglobulin gene hypermutation in germinal centers is independent of the RAG-1 V(D)J recombinase
62. - Germinal center B cells can express up to 80 mutations in the variable region of their IgD transcripts
63. The normal counterpart of IgD myeloma cells in germinal center display extensively mutated Ig V(H) gene, Cu-Cδ switch, and λ light chain expression
64. The molecular basis of somatic hypermutation of immunoglobulin genes
65. The systemic amyloidoses
66. A molecular model for self-assembly of amyloid fibrils: Immunoglobulin light chains
67. Bence Jones proteins and light chains of immunoglobulins: Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda)
68. Evidence that amyloidogenic light chains undergo antigen-driven selection
69. Follicular lymphoma immunoglobulin κ light chains are affected by the antigen selection process, but to a lesser degree than their partner heavy chains
70. Selection of immunoglobulin diversity gene reading frames in B-cell lymphoproliferative disorders
71. T(14;18) chromosomal translocation in follicular lymphoma: An event occuring with almost equal frequency both at the D to J(H) and at later stages in the rearrangement process of the immunoglobulin heavy chain gene locus
72. Molecular analysis of bcl-1/IgH junctional sequences in mantle cell lymphoma: Potential mechanisms of the t(11;14) chromosomal translocation
73. Codon bias targets mutation
74. Modifying the sequence of an immunoglobulin V-gene alters the resulting pattern of hypermutation
75. Both DNA strands of antibody genes are hypermutation targets
76. Monitoring and interpreting the intrinsic features of somatic hypermutation
77. Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease
78. Amino acid insertions and deletions contribute to diversify the human lg repertoire
79. Clonal selection and learning in the antibody system
80. Molecular insights to the immunopathogenesis of follicular lymphoma
81. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients
82. 1 peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma
83. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma
84. Autotransplants in myeloma: What have we learned
85. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests before and after autografting
86. Autotransplants in myeloma: What have we learned
87. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
88. Induction of immune responses in patients with B cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
89. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
90. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines
91. DNA immunization induces protective immunity against B-cell lymphoma
92. Idiotype/granulocyte-macrophage colony stimulating factor fusion protein as a vaccine for B-cell lymphoma
93. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation